Shows & Panels
Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- American Readiness: Renewable Power and Efficiency Technologies
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal News Radio's National Cyber Security Awareness Month Special Panel Discussion
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- Government Perspectives on Mobility and the Cloud
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- The New Generation of Database
- Reimagining the Next Generation of Government
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
Severe US flu season helped Roche's Q1 sales
Thursday - 4/11/2013, 8:11am EDT
GENEVA (AP) -- Strong sales of new cancer drugs and a severe U.S. flu season helped lift Swiss drug maker Roche Holding AG's revenue by 6 percent in the first quarter.
The world's biggest manufacturer of cancer drugs said Thursday that sales rose to 11.56 billion Swiss francs ($12.4 billion) during the first three months of the year, up from 11.03 billion francs in the same period last year.
Severin Schwan, the chief executive of Basel, Switzerland-based pharmaceutical company, described it as "a very good start in 2013" and attributed much of the advance to an 84 percent increase in Tamiflu sales during the U.S. flu season. Also helping were two new cancer drugs that the company hopes will mirror the performance of its three top-selling cancer medicines MabThera/Rituxan, Herceptin and Avastin.
"The launch of two new cancer drugs, Kadcyla in the United States and Perjeta in Europe, will help to further improve our leading market position in oncology," Schwan said in a statement.
The company also said there was strong demand for its ovarian cancer drug Avastin in Europe.
Roche, which reports its earnings only every six months, said group sales for 2013 are expected to grow in line with last year's 4 percent increase. Unlike many of its major competitors, the company benefits from having strong sellers whose patents are not expiring soon.
But like many other major Swiss companies it has battled against the strength of the franc in recent years, a situation that somewhat reversed in 2012. Roche said the rise of the franc against the yen by 13 percent impacted its group sales in francs by 1 percent.
Shares in Roche were trading up 0.2 percent Thursday morning at 226 francs on the Zurich exchange.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.